The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia
EMBO Reports · 2023
DOI: 10.15252/embr.202256420 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Reports, 2023. Verfasst von Bettina Röder und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5 + B cells. BCR signaling is regulated by the inhibitory co‐receptor Siglec‐G and Siglec‐G‐deficient mice have an enlarged CD5 + B1a cell population. Here, we determine how Siglec‐G expression influences the severity of CLL. Our results show that Siglec‐G deficiency leads to earlier onset and more severe course of the CLL‐like disease in the murine Eμ‐TCL1 model. In contrast, mice overexpressing Siglec‐G on the B cell surface are almost completely protected from developing CLL‐like disease. Furthermore, we observe a downmodulation of the human ortholog Siglec‐10 from the surface of human CLL cells. These results demonstrate a critical role for Siglec‐G in disease progression in mice, and suggest that a similar mechanism for Siglec‐10 in human CLL may exist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
- Medical Faculty, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
ORCID-Profile: Bettina Budeus, Maria Dampmann, Lars Nitschke
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Röder, B., Fahnenstiel, H., Schäfer, S., Budeus, B., Dampmann, M., Eichhorn, M., Angermüller, S., Brost, C., Winkler, T. H., Seifert, M., & Nitschke, L. (2023). The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia. EMBO Reports. https://doi.org/10.15252/embr.202256420
Vancouver
Röder B, Fahnenstiel H, Schäfer S, Budeus B, Dampmann M, Eichhorn M, et al. The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia. EMBO Reports. 2023. doi:10.15252/embr.202256420
BibTeX
@article{Rder2023,
author = {Röder, Bettina and Fahnenstiel, Hannah and Schäfer, Simon and Budeus, Bettina and Dampmann, Maria and Eichhorn, Melanie and Angermüller, Sieglinde and Brost, Claudia and Winkler, Thomas H and Seifert, Marc and Nitschke, Lars},
title = {The inhibitory receptor Siglec‐G controls the severity of chronic lymphocytic leukemia},
journal = {EMBO Reports},
year = {2023},
doi = {10.15252/embr.202256420}
}
EUVIMED